Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays

17 февраля 2020 г. обновлено: GlaxoSmithKline
The purpose of this study is to develop and characterize immunological assays on blood samples.

Обзор исследования

Статус

Завершенный

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

99

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Brussels, Бельгия, 1070
        • GSK Investigational Site
      • Bruxelles, Бельгия, 1000
        • GSK Investigational Site

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 65 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Written informed consent obtained from the subject.
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • A male or female between, and including, 18 and 65 years of age at study start.
  • Evidence of chronic hepatitis B infection as per medical record.
  • Female subjects of non-childbearing potential may be enrolled in the study.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.

In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:

Group A: Immune tolerant patients

  • Viral load: > 2x107 IU/mL of HBV DNA
  • HBeAg positive
  • Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients
  • Viral load: > 2x104 IU/mL of HBV DNA
  • HBeAg positive
  • Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers
  • Viral load: not exceeding 2x103 IU/mL of HBV DNA
  • HBeAg negative
  • Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients
  • Viral load: > 2x103 IU/mL of HBV DNA
  • HBeAg negative
  • Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy

Exclusion Criteria:

  • Any hepatitis B specific treatment prior to blood sampling at Visit 1.
  • Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.
  • Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.
  • Receipt of blood products within 120 days prior to study entry (Visit 1).
  • Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).
  • Receipt of interferon within 120 days prior to study entry (Visit 1).
  • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).
  • Pregnant or lactating female.
  • History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.
  • History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).
  • History of major congenital defect.
  • Subjects with a history of, or current, alcohol or substance abuse.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Другой
  • Распределение: Нерандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Другой: Immune tolerant patients Group
Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Другой: HBeAg positive Group
HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Другой: Inactive carriers Group
Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Другой: HBeAg negative Group
HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
At the time of the visit for each subject (i.e., Day 0)

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Временное ограничение: At the time of the visit for each subject (i.e., Day 0)

The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17.

Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).

At the time of the visit for each subject (i.e., Day 0)

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

29 апреля 2010 г.

Первичное завершение (Действительный)

20 февраля 2012 г.

Завершение исследования (Действительный)

20 февраля 2012 г.

Даты регистрации исследования

Первый отправленный

1 апреля 2010 г.

Впервые представлено, что соответствует критериям контроля качества

1 апреля 2010 г.

Первый опубликованный (Оценивать)

2 апреля 2010 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

25 февраля 2020 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

17 февраля 2020 г.

Последняя проверка

1 февраля 2020 г.

Дополнительная информация

Термины, связанные с этим исследованием

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться